/**
 * Quick Review content for Topic 15 - Secondary hemostasis: blood clotting (coagulation)
 * Auto-generated by Quick Review Generator
 */
const topic15QuickReview = {
  topicId: 'topic-15',
  topicNumber: 15,
  learningObjectives: {
    'lo-1': {
      title: '>>Define the coagulation factors, their nomenclature, site of synthesis, and the mechanism of their action.<<',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'Coagulation Factors: Nomenclature & Classification', critical: true },
        { type: 'paragraph', text: 'Coagulation factors are plasma proteins in a cascade leading to fibrin clot formation. Numbered with Roman numerals I-XIII; activated forms denoted with "a" (e.g., IIa = thrombin).', critical: true },
        { type: 'list', intro: 'Classification by function:', items: [
          'Enzymes: Serine proteases (II, VII, IX, X, XI, XII) + transglutaminase (XIII)',
          'Cofactors: V (proaccelerin), VIII (antihemophilic factor)',
          'Substrate: I (fibrinogen)',
          'Others: III (tissue factor), IV (Ca²⁺)'
        ], critical: true },
        { type: 'header', text: 'Vitamin K-Dependent Factors', critical: true },
        { type: 'paragraph', text: 'Four factors require vitamin K for γ-carboxylation: II (prothrombin), VII (proconvertin), IX (Christmas factor), X (Stuart-Prower factor). All synthesized in liver.', critical: true },
        { type: 'header', text: 'Key Factor Mechanisms' },
        { type: 'table', headers: ['Factor', 'Mechanism of Action', 'Clinical Note'], rows: [
          ['I (Fibrinogen)', 'Converted to fibrin by thrombin → clot mesh', 'Substrate for clot'],
          ['II (Prothrombin)', 'Converted to thrombin by prothrombinase → activates I, V, VIII, XI, XIII', 'Central amplifier'],
          ['VII', 'Binds tissue factor → activates X (extrinsic pathway)', 'Initiates extrinsic'],
          ['VIII', 'Cofactor for IXa in tenase complex → activates X', 'Deficiency = Hemophilia A'],
          ['IX', 'With VIIIa forms tenase → activates X', 'Deficiency = Hemophilia B'],
          ['X', 'With Va forms prothrombinase → activates II', 'Convergence point'],
          ['XIII', 'Cross-links fibrin strands via covalent bonds', 'Stabilizes clot']
        ], critical: true },
        { type: 'keypoint', text: 'Thrombin (IIa) is the key amplifying enzyme: converts fibrinogen to fibrin AND activates V, VIII, XI, XIII in positive feedback.', critical: true }
      ]
    },
    'lo-2': {
      title: '>>Describe the extrinsic pathway.<< Describe the intrinsic pathway and the contact phase.',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'Extrinsic Pathway: Rapid Response (30 seconds)', critical: true },
        { type: 'paragraph', text: 'Initiated by external trauma and tissue damage exposing tissue factor.', critical: true },
        { type: 'steps', intro: 'Extrinsic pathway cascade:', items: [
          'Tissue Factor (Factor III) exposed from damaged subendothelial cells',
          'Factor VII binds TF with Ca²⁺ → forms TF-VII complex',
          'TF-VII complex activates VII to VIIa → TF-VIIa complex',
          'TF-VIIa activates Factor X to Xa (convergence to common pathway)',
          'Thrombin provides positive feedback, enhancing V, VIII, XI activation'
        ], critical: true },
        { type: 'clinical', text: 'Evaluated by Prothrombin Time (PT) test. Normal: 18-20 seconds.' },
        { type: 'header', text: 'Intrinsic Pathway: Slower Response (4-6 minutes)', critical: true },
        { type: 'paragraph', text: 'Initiated by endothelial damage or negatively charged surfaces (collagen, glass). All factors present in blood.', critical: true },
        { type: 'steps', intro: 'Contact Phase (surface activation):', items: [
          'Factor XII (Hageman factor) contacts negatively charged surfaces → activates to XIIa',
          'HMWK (high-molecular-weight kininogen) and prekallikrein facilitate',
          'Prekallikrein → kallikrein (enhances XII activation, feedback loop)'
        ], critical: true },
        { type: 'steps', intro: 'Intrinsic pathway cascade:', items: [
          'XIIa activates XI to XIa (with HMWK cofactor)',
          'XIa activates IX to IXa (requires Ca²⁺)',
          'IXa + VIIIa + Ca²⁺ + phospholipids → intrinsic tenase complex',
          'Intrinsic tenase activates X to Xa (convergence to common pathway)'
        ], critical: true },
        { type: 'clinical', text: 'Evaluated by aPTT (activated partial thromboplastin time). Factor VIII deficiency = Hemophilia A; Factor IX deficiency = Hemophilia B.' },
        { type: 'keypoint', text: 'Contact phase essential in vitro (lab tests) but minor role in vivo (physiological hemostasis).', critical: false }
      ]
    },
    'lo-3': {
      title: '>>Expound the common phase of blood coagulation (convergence of extrinsic and intrinsic pathways) and the formation of the stable fibrin mesh.<<',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'Common Pathway: Convergence at Factor X', critical: true },
        { type: 'paragraph', text: 'Both extrinsic and intrinsic pathways activate Factor X to Xa. This is the convergence point leading to stable fibrin mesh.', critical: true },
        { type: 'comparison',
          left: {
            title: 'Extrinsic Tenase',
            items: ['TF-VIIa complex', '+ Ca²⁺ + phospholipids', 'Activates X to Xa']
          },
          right: {
            title: 'Intrinsic Tenase',
            items: ['IXa-VIIIa complex', '+ Ca²⁺ + phospholipids', 'Activates X to Xa']
          }
        },
        { type: 'header', text: 'Formation of Prothrombinase Complex', critical: true },
        { type: 'steps', intro: 'Common pathway sequence:', items: [
          'Factor Xa binds Va + Ca²⁺ + phospholipids (on platelet surface) → prothrombinase complex',
          'Prothrombinase converts prothrombin (II) to thrombin (IIa)',
          'Thrombin converts fibrinogen (I) to fibrin monomers',
          'Fibrin monomers spontaneously polymerize → fibrin network',
          'Thrombin activates XIII to XIIIa',
          'XIIIa cross-links fibrin strands via covalent bonds → stable insoluble mesh'
        ], critical: true },
        { type: 'header', text: 'Thrombin: The Central Amplifier' },
        { type: 'list', intro: 'Thrombin (IIa) multiple actions:', items: [
          'Converts fibrinogen → fibrin monomers',
          'Activates XIII → XIIIa (fibrin cross-linking)',
          'Activates V, VIII, XI (positive feedback amplification)'
        ], critical: true },
        { type: 'keypoint', text: 'Stable fibrin mesh = framework trapping platelets and RBCs, sealing injury, withstanding blood flow mechanical stress.', critical: true }
      ]
    },
    'lo-4': {
      title: '>>Explain the role of vitamin K in the synthesis of the so-called vitamin K-dependent coagulation factors.<<',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'Vitamin K-Dependent Factors', critical: true },
        { type: 'paragraph', text: 'Factors II (prothrombin), VII, IX, X, plus anticoagulants Protein C and Protein S require vitamin K for function.', critical: true },
        { type: 'header', text: 'Vitamin K Cycle: Post-Translational Modification', critical: true },
        { type: 'steps', intro: 'γ-Carboxylation cycle:', items: [
          'Enzyme γ-glutamyl carboxylase (liver) catalyzes reaction',
          'Reduced vitamin K (hydroquinone) = cofactor',
          'Glutamic acid residues → γ-carboxyglutamic acid (Gla) residues',
          'Vitamin K oxidized to vitamin K epoxide during reaction',
          'Vitamin K epoxide reductase (VKOR) regenerates active reduced vitamin K',
          'Cycle allows continuous reuse of vitamin K'
        ], critical: true },
        { type: 'header', text: 'Function of Gla Residues', critical: true },
        { type: 'paragraph', text: 'Gla residues enable factors to bind Ca²⁺ ions effectively. This calcium binding is essential for proper factor configuration, allowing them to anchor to phospholipid surfaces of platelets and endothelial cells.', critical: true },
        { type: 'keypoint', text: 'Without Ca²⁺ binding, coagulation factors cannot function → bleeding tendency.', critical: true },
        { type: 'header', text: 'Clinical Implications' },
        { type: 'comparison',
          left: {
            title: 'Vitamin K Deficiency',
            items: ['Non-functional proteins', 'Cannot bind Ca²⁺', 'Increased bleeding (coagulopathy)']
          },
          right: {
            title: 'Warfarin (Anticoagulant)',
            items: ['Inhibits VKOR enzyme', 'Prevents vitamin K regeneration', 'Reduces functional factor synthesis']
          }
        },
        { type: 'clinical', text: 'Warfarin used therapeutically to prevent thrombotic events (DVT, PE, stroke in AFib).' }
      ]
    },
    'lo-5': {
      title: 'What is the "placenta sanguis"? Define the process of clot retraction, define the term serum and compare its composition with the blood plasma.',
      isCritical: false,
      blocks: [
        { type: 'header', text: 'Placenta Sanguis (Historical Term)' },
        { type: 'paragraph', text: 'The initial blood mass formed after injury before it retracts or stabilizes into solid clot.' },
        { type: 'header', text: 'Clot Retraction' },
        { type: 'paragraph', text: 'Post-clot formation process where the clot contracts, becoming denser and smaller.' },
        { type: 'steps', intro: 'Mechanism of retraction:', items: [
          'Platelets within clot contract via actin-myosin components (muscle-like)',
          'Fibrin threads pulled tight → clot size reduces',
          'Wound edges drawn closer together',
          'Liquid portion expelled from clot',
          'Aids tissue repair and stabilizes clot structure'
        ] },
        { type: 'header', text: 'Serum vs Plasma: Definitions' },
        { type: 'comparison',
          left: {
            title: 'Blood Plasma',
            items: ['Liquid collected WITH anticoagulant', 'Clotting prevented', 'Contains ALL clotting factors', 'Includes fibrinogen']
          },
          right: {
            title: 'Serum',
            items: ['Liquid AFTER blood clots', 'Clotting factors consumed', 'Fibrinogen removed (used in clot)', 'Centrifuged to separate']
          }
        },
        { type: 'header', text: 'Composition Comparison' },
        { type: 'table', headers: ['Component', 'Plasma', 'Serum'], rows: [
          ['Water & electrolytes', 'Yes', 'Yes'],
          ['Fibrinogen', 'Yes', 'No (used in clot)'],
          ['Clotting factors (II, V, VII, VIII, etc.)', 'Yes', 'No (consumed)'],
          ['Antibodies & antigens', 'Yes', 'Yes'],
          ['Hormones', 'Yes', 'Yes'],
          ['Non-clotting proteins (albumin)', 'Yes', 'Yes']
        ] },
        { type: 'keypoint', text: 'Serum + coagulation factors = Plasma. Serum is plasma minus clotting components.' }
      ]
    },
    'lo-6': {
      title: 'Compare prothrombin time and coagulation time.',
      isCritical: false,
      blocks: [
        { type: 'header', text: 'Prothrombin Time (PT) vs Coagulation Time' },
        { type: 'comparison',
          left: {
            title: 'Prothrombin Time (PT)',
            items: ['Measures: Time to clot after adding tissue factor + Ca²⁺', 'Evaluates: Extrinsic + Common pathways', 'Normal: 18-20 seconds', 'Fast and specific']
          },
          right: {
            title: 'Coagulation Time (Lee-White)',
            items: ['Measures: Whole blood clotting without external factors', 'Evaluates: Intrinsic + Common pathways', 'Normal: 5-8 minutes', 'Slower, less specific']
          }
        },
        { type: 'header', text: 'Pathway Differences' },
        { type: 'table', headers: ['Test', 'Pathways Assessed', 'Key Factors'], rows: [
          ['PT', 'Extrinsic + Common', 'VII, V, X, II (prothrombin), I (fibrinogen)'],
          ['Coagulation Time', 'Intrinsic + Common', 'XII, XI, IX, VIII + common pathway factors']
        ] },
        { type: 'header', text: 'Clinical Use' },
        { type: 'list', intro: 'PT applications:', items: [
          'Monitor warfarin anticoagulant therapy (reported as INR)',
          'Assess bleeding disorders of extrinsic pathway',
          'Liver function (factors synthesized in liver)',
          'More commonly used, more specific'
        ] },
        { type: 'list', intro: 'Coagulation time applications:', items: [
          'General clotting ability assessment',
          'Less specific (influenced by many factors)',
          'Less commonly used in modern practice'
        ] },
        { type: 'keypoint', text: 'PT is quicker (seconds) and more specific; Coagulation time takes longer (minutes) and is more general.' }
      ]
    },
    'lo-7': {
      title: 'Define INR, its calculation and significance.',
      isCritical: false,
      blocks: [
        { type: 'header', text: 'International Normalized Ratio (INR)' },
        { type: 'paragraph', text: 'Standardized measure of blood clotting tendency. Ensures consistency across laboratories with varying thromboplastin reagent sensitivities.' },
        { type: 'header', text: 'INR Calculation' },
        { type: 'formula', formula: 'INR = (PT patient ÷ PT normal control)^ISI', explanation: 'ISI = International Sensitivity Index from reagent manufacturer', critical: true },
        { type: 'list', intro: 'Formula components:', items: [
          'PT patient: Patient\'s prothrombin time',
          'PT normal control: Average PT of healthy individuals',
          'ISI: Reagent sensitivity compared to international standard'
        ] },
        { type: 'header', text: 'INR Reference Ranges' },
        { type: 'table', headers: ['Condition', 'INR Range', 'Interpretation'], rows: [
          ['Normal (no anticoagulation)', '0.8 - 1.2', 'Normal clotting'],
          ['Warfarin therapy (most indications)', '2.0 - 3.0', 'Therapeutic anticoagulation'],
          ['Mechanical heart valves', '2.5 - 3.5', 'Higher anticoagulation needed'],
          ['INR > 3.0', 'Elevated', 'Increased bleeding risk (clotting too slowly)'],
          ['INR < 2.0 (on warfarin)', 'Subtherapeutic', 'Higher thrombosis risk (clotting too quickly)']
        ], critical: true },
        { type: 'header', text: 'Clinical Significance' },
        { type: 'list', intro: 'Why INR matters:', items: [
          'Standardizes PT results regardless of thromboplastin reagent used',
          'Allows consistent global patient monitoring',
          'Primary tool for monitoring oral anticoagulant therapy (warfarin)',
          'Ensures safe and effective medication dosing'
        ] },
        { type: 'clinical', text: 'High INR (>3.0) = bleeding risk. Low INR on warfarin (<2.0) = thrombosis risk. Dose adjustments needed.' },
        { type: 'keypoint', text: 'INR eliminates laboratory variation, enabling reliable warfarin monitoring worldwide.' }
      ]
    }
  }
};

export default topic15QuickReview;
